<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820506</url>
  </required_header>
  <id_info>
    <org_study_id>SDUSF12015163 1 (198)1</org_study_id>
    <nct_id>NCT02820506</nct_id>
  </id_info>
  <brief_title>Sentinel Node Mapping in Women With Endometrial and Cervical Cancer</brief_title>
  <acronym>SENTIREC II</acronym>
  <official_title>Sentinel Node Mapping With Robotic Assisted Near Infra-red Fluorescent Imaging in Women With Cervical and Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the feasibility of applying the SLN mapping technique in
      combination with FDG-PET/CT imaging in women with high-risk histology endometrial cancer and
      in patients with cervical cancer tumour size 2-4 cm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>2 years</time_frame>
    <description>Sensitivity of sentinel lymph node mapping compared to the sensitivity of sentinel lymph node mapping combined with removal of PET-positive lymph nodes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value</measure>
    <time_frame>2 years</time_frame>
    <description>Negative predictive value of sentinel lymph node mapping compared to the combination of sentinel lymph node mapping and removal of PET-positive lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity</measure>
    <time_frame>2 years</time_frame>
    <description>Specificity of sentinel lymph node mapping compared to the combination of sentinel lymph node mapping and removal of PET-positive lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value</measure>
    <time_frame>2 years</time_frame>
    <description>Positive predictive value of sentinel lymph node mapping compared to the combination of sentinel lymph node mapping and removal of PET-positive lymph nodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of lymph node metastasis</measure>
    <time_frame>2 years</time_frame>
    <description>Prevalence of lymph node metastasis in the pelvis and paraaortic area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of lymphedema</measure>
    <time_frame>3 years</time_frame>
    <description>Using patient reported outcome measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of lymphedema</measure>
    <time_frame>3 years</time_frame>
    <description>Using patient reported outcome measures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life rate</measure>
    <time_frame>3 years</time_frame>
    <description>Using patient reported outcome measures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Uterine Neoplasms</condition>
  <arm_group>
    <arm_group_label>High risk endometrial cancer</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervical cancer tumor size 2-4 cm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive sentinel node mapping, followed by removal of PET-positive lymph nodes and finally conventional pelvic lymphadenectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SLN mapping and removal of PET-positive lymph nodes</intervention_name>
    <description>Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes</description>
    <arm_group_label>High risk endometrial cancer</arm_group_label>
    <arm_group_label>Cervical cancer tumor size 2-4 cm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study IIA: Patients with cervical cancer, FIGO IB1, tumor size 2-4 cm

          -  Study IIB: Patients with high risk endometrial cancer, presumed FIGO I, type 1
             histology grade 3 Endometrioid adenocarcinoma or type 2 histology (serous-, clearcel-,
             carcinosarcoma or undifferentiated adenocarcinoma.

        Exclusion Criteria:

          -  Prior PL

          -  Known allergy towards ICG and/or iodine (ICG contains 5% sodium iodine)

          -  Women included in other studies affecting outcome-measures of the present study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sara E Sponholtz, MD</last_name>
    <phone>+45 28439977</phone>
    <email>sara.elisabeth.sponholtz2@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara E Sponholtz, MD</last_name>
      <phone>+45 28439977</phone>
      <email>Sara.Elisabeth.Sponholtz@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara E Sponholtz, MD</last_name>
      <phone>+45 28439977</phone>
      <email>Sara.Elisabeth.Sponholtz@rsyd.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara E Sponholtz, MD</last_name>
      <phone>+45 28439977</phone>
      <email>Sara.Elisabeth.Sponholtz@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern Denmark</investigator_affiliation>
    <investigator_full_name>Sara Sponholtz</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>robotic surgery procedures</keyword>
  <keyword>indocyanine green</keyword>
  <keyword>sentinel lymph node mapping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

